JUNO THERAPEUTICS INC (JUNO) Stock News
NASDAQ:JUNO - Nasdaq - US48205A1097
JUNO Latest News, Press Relases and Analysis
Chiliz, Celo Among Top Crypto Movers In 24H
Pulled from Benzinga Pro here's the list of the top crypto gainers and losers at the ti...
Want To Buy Crypto? Check Out The Top Movers For Today
After pulling data from Benzinga Pro the following is the list of top crypto gainers an...
Stocks making the biggest moves premarket: XL, QCOM, AMZN, NWL & more
Some of the names on the move ahead of the open.
Orca Bio Emerges as $1 Billion-Plus Biotech With Mystery Backer
Orca Bio raised $192 million from Lightspeed Venture Partners and an unnamed investor for its experimental cell therapy platform.
A Biotech Merger Wave Looms Despite Political Pitfalls
Expect broad-based biotech M&A this year, says Jefferies.
Juno Therapeutics Gets a Hold Rating from Raymond James
In a report released today, Reni Benjamin from Raymond James maintained a Hold rating on Juno Therapeutics (NASDAQ: JUNO). The company’s shares closed on Monday at $86.96, close to its 52-week high of $87.01. Benjamin observed: “We are dropping coverage of Juno Therapeutics (JUNO) given that Celgene Corporation (CELG/$91.19/Market Perform) completed the acquisition of Juno
The post Juno Therapeutics Gets a Hold Rating from Raymond James appeared first on Analyst Ratings.
These Are The Top Stocks That Retail Investors Bought And Sold In A Wild February
Apple, Amazon, General Electric and Ford Motor ranked among top stock buys for retail investors last month even as the stock market entered a brief correction.
Biotechs Buffeted by Macro News But Should Continue to Outperform
Biotechs outperform in 2018 having recovered most of their losses from last week’s volatility caused by dire tariff talk and higher interest rates, raising concerns about the impact on global growth.
Biotech Crushing the Market: Best ETFs & Stocks YTD
Biotechnology sector, which includes the fast-growing companies in the health care world, are easily crushing the overall market and broader health care sector so far this year.
Gilead’s Latest Deal Is Good News for Biotechs
Gilead's latest partnership shows that gene-editing technology firms could have more gains to come.
Juno Therapeutics (JUNO) remains a Buy This Week
The Buy for Juno Therapeutics (JUNO) this week is based on the most recent relative pricing of its shares and market intelligence.
Treatment Debates Won’t Slow Down Biotechs
Current debates about CAR-T side affects shouldn't keep the therapies from advancing, argues Guggenheim.
Celgene Receives Antitrust Clearance for Juno Acquisition
Mentions: CELG
Biotechs: Still Well Placed For More Gains
The cold winds of February cut into the market as stocks found themselves going in an unaccustomed direction. Sliding like a toboggan, stocks last week experienced the sharpest correction in over 50 years, reaching the -10% mark within a week.
How CEO's of Biotech are Incentivized and What This Means for Investors
The 10 Best ETFs of January 2018
These were the some of the best ETFs in January, as each outperformed the S&P 500 by at least 5% or more. Here's what investors need to know about each ETF.
Biotech M&A: Sanofi SA (ADR) Inks 2nd Multi-Billion Dollar Deal in a Week
Sanofi (SNY) inks second multi-dollar deal this month. Since the earlier deal last Monday, SNY stock gained 2.6% in a week.
You Definitely Should Buy Celgene Corporation Stock After Earnings Beat
Celgene shares have traded mixed since reporting earnings. However, management told a reassuring story and CELG stock is one to buy at these levels.
Celgene: Headwinds For Otezla Could Weigh
CELG beat Q4 revenue expectations on 20% price hikes for Revlimid. Once price hikes run their course CELG could face headwinds for Otezla. In the near term, it could be difficult to justify CELG's trading multiple which exceeds 16x run-rate EBITDA.
5 Biotech and Pharmaceutical Stocks Going Bonkers
These biotech and pharmaceutical stocks are soaring insanely high right now. Here's what investors should know about each of these hot stocks to buy.
These 27 S&P 500 stocks are blowing away the market with gains of 15% or more this month
Measuring the S&P: 23% of its components are up at least 10% so far in 2018 while 35 are in the red.
The Law Offices of Vincent Wong Reminds Investors of an Investigation of Juno Therapeutics, Inc. in Connection with the Sale of the Company to Celgene Corp.
The Law Offices of Vincent Wong Notifies Investors of an Investigation of Juno Therapeutics, Inc. in Connection with the Sale of the Company to Celgene Corp.
Why Investors Should Stay Long Eli Lilly and Co Stock
LLY stock had a sudden drop on Jan. 22, but Eli Lilly and Co recovered the bulk of its losses, which means bulls can stay long for the time being.
WeissLaw LLP Investigates Juno Therapeutics Inc. Acquisition
Mentions: CELG
Juno Therapeutics, Inc. (JUNO): Downgrade News
JUNO – Standpoint Research cuts to a hold. Stock price at the time of this analyst call was $85.86.
5 biotech buyout candidates you should look at right now
Jeff Reeves looks at five biotechs that might be buyout candidates in the wake of the big Juno deal.